---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-027808"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:46:59.140902+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# ProKidney provides final Phase 2 RMCL-002 data; specifics not in filing text

## Summary
- Company furnished investor presentation with final data from Phase 2 RMCL-002 clinical trial.
- Presentation available on ProKidney's website; full data not included in 8-K excerpt.
- Trial targets dialysis prevention; efficacy/safety figures not disclosed in filing.
- No financial or operational updates beyond the trial data release.

## SEC filing metadata
- accession: 0001140361-24-027808
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000114036124027808/0001140361-24-027808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000114036124027808/ef20030179_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-027808
- JSON: https://secwatch.observer/filing/0001140361-24-027808.json
- Plain text: https://secwatch.observer/filing/0001140361-24-027808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.